
## Carmen S Ng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9201466/publications.pdf Version: 2024-02-01



CARMEN S NC

#	Article	IF	CITATIONS
1	Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015–2018. Vaccine, 2022, 40, 247-254.	1.7	5
2	Impact of the COVID-19 Pandemic on Chronic Disease Care in India, China, Hong Kong, Korea, and Vietnam. Asia-Pacific Journal of Public Health, 2022, 34, 392-400.	0.4	17
3	The impact of road safety policies in a deregulated alcohol tax environment in Hong Kong: a 15â€year time series analysis. Addiction, 2022, , .	1.7	2
4	The impact of alcohol pricing policies on public health in Hong Kong, China: A modelling study. The Lancet Regional Health - Western Pacific, 2022, 26, 100510.	1.3	2
5	Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study. PLoS Medicine, 2021, 18, e1003692.	3.9	9
6	Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis. Value in Health, 2021, 24, 1059-1067.	0.1	16
7	Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017. Vaccine, 2020, 38, 1746-1752.	1.7	29
8	Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65â€years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010–December 2018. Vaccine, 2020, 38, 1476-1480.	1.7	11
9	Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010–2017. Vaccine, 2020, 38, 1137-1143.	1.7	41
10	Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010–2016. Vaccine, 2020, 38, 1076-1083.	1.7	50
11	Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005–2016. Vaccine, 2020, 38, 6291-6298.	1.7	10
12	Association Between Vaccine Exemption Policy Change in California and Adverse Event Reporting. Pediatric Infectious Disease Journal, 2020, 39, 369-373.	1.1	5
13	Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014–2018. Open Forum Infectious Diseases, 2020, 7, ofaa516.	0.4	5
14	Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. Vaccine, 2019, 37, 3730-3734.	1.7	9
15	Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. Journal of Allergy and Clinical Immunology, 2019, 143, 1465-1473.	1.5	83
16	Post-licensure surveillance of trivalent adjuvanted influenza vaccine (allV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016–June 2018. Vaccine, 2019, 37, 1516-1520.	1.7	15
17	Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018. Morbidity and Mortality Weekly Report, 2019, 68, 91-94.	9.0	37
18	Adverse events after vaccination among HIV-positive persons, 1990–2016. PLoS ONE, 2018, 13, e0199229.	1.1	8

#	Article	IF	CITATIONS
19	Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008–2016. Human Vaccines and Immunotherapeutics, 2018, 14, 1-5.	1.4	5
20	Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010–2015. Vaccine, 2017, 35, 1758-1763.	1.7	28
21	On the electrostatic component of protein-protein binding free energy. PMC Biophysics, 2008, 1, 2.	2.2	49